<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393363</url>
  </required_header>
  <id_info>
    <org_study_id>N-20190068</org_study_id>
    <nct_id>NCT04393363</nct_id>
  </id_info>
  <brief_title>Early Detection of Neuropathy and Cognitive Impairment Following Treatment for Haematological Malignancies</brief_title>
  <acronym>NOVIT1</acronym>
  <official_title>Early Detection and Prevention of Neuropathy and Cognitive Impairment Following Treatment for Haematological Malignancies (the NOVIT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy-induced peripheral neuropathy (CIPN) is a common, but not well understood&#xD;
      complication to treatment with chemotherapy. In this study the investigators will investigate&#xD;
      a novel method for early detection of CIPN and compare it to other methods in patients&#xD;
      treated for haematological cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Haematological malignancies can be treated with chemotherapy if the patient tolerates the&#xD;
      treatment. However, many patients develop complications during treatment including&#xD;
      chemotherapy-induced peripheral neuropathy (CIPN) and/or impaired memory. Even though it is a&#xD;
      well-known complication, no gold standard for CIPN assessment is known. Besides chemotherapy&#xD;
      reduction or cessation, there is so far no sufficient prevention or treatment, therefore&#xD;
      early detection and intervention is crucial.&#xD;
&#xD;
      The main purpose of this study is to find a reliable test for chemotherapy-induced peripheral&#xD;
      neuropathy (CIPN) in order to predict early signs of CIPN. All included patients has to be&#xD;
      scheduled for treatment with vincristine, bortezomib or lenalidomide regardless of&#xD;
      haematological malignancy. Neuropathy and cognitive impairment will be tested at baseline&#xD;
      (prior to treatment with chemotherapy), before each treatment course, 1 month after treatment&#xD;
      and finally 1 year after onset of chemotherapy. CIPN will be examined by different methods:&#xD;
      Clinician-based assessment, objective neurophysiological parameters and patient-reported&#xD;
      outcome. A novel test using Perception Threshold Tracking (PTT), developed at Aalborg&#xD;
      University, is included in the study. The test investigates the nerve excitability in both&#xD;
      large and small fiber nerve fibers using two different electrodes. Blood samples will be&#xD;
      collected, stored, and analyzed for deficiencies correlated to neuropathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in neuropathy assessed by change in the neurotoxicity (ntx)-subscale of the FACT/GOG-Ntx-13-Score</measure>
    <time_frame>0-12 months</time_frame>
    <description>A patient questionnaire with focus on Quality of Life and neuropathy. Range 0-52 with higher score meaning better Quality of Life (less neuropathy). Neuropathy will be defined as a 10 % reduction in the Ntx-score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in nerve excitability assessed by Perception Threshold Tracking</measure>
    <time_frame>0-12 months</time_frame>
    <description>Assessment of nerve excitability in both large and small fiber nerves measured by two different electrodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in The National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE)</measure>
    <time_frame>0-12 months</time_frame>
    <description>A grading scale 1-5 (with 5 as the worst) for neuropathy evaluated by the medical doctor based on the patients' symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Total Neuropathy Score-Clinical</measure>
    <time_frame>0-12 months</time_frame>
    <description>A score based on clinical evaluation (pin and vibration sensibility, strength and reflexes) and subjective reports from the patient (sensory, motor and autonomic symptoms). The score grades from 0-28 with 28 at worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (The total FACT/GOG-Ntx-score)</measure>
    <time_frame>0-12 months</time_frame>
    <description>A patient questionnaire with focus on Quality of Life and neuropathy. This part will focus on Quality of Life. Score range from 0-160 with higher score meaning higher Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>0-12 months</time_frame>
    <description>A quick and easy method to assess mild cognitive disturbance based on following parameters: Awareness, concentration, executive function, memory, abstract thinking, calculating abilities and orientation. The score is 0-30, score &gt; 26 is normal (without cognitive disturbance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the score for FACT/GOG-cog</measure>
    <time_frame>0-12 months</time_frame>
    <description>A patient questionnaire used to assess cognitive function. The score is measured from 0-132 with higher score meaning better Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VagusTM Test</measure>
    <time_frame>0-12 months</time_frame>
    <description>A measurement for autonomic neuropathy by evaluation of heart rate in different positions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bioimpendance</measure>
    <time_frame>0-12 months</time_frame>
    <description>Measurement of body composition in order to investigate loss of muscle mass, which can influence motor function and imitate or mask motor neuropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vitamin B12-level in blood test</measure>
    <time_frame>0-12 months</time_frame>
    <description>Measurement of deficiency/functional deficiency</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chemotherapy-induced Peripheral Neuropathy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood/plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Haematological patients scheduled for (but not started) treatment with vincristine,&#xD;
        bortezomib or lenalidomid regardless of type of haematological malignancy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, age â‰¥ 18 years&#xD;
&#xD;
          -  Scheduled for treatment with Vincristine (R-CHOP, CHOP, R-CHOEP, CHOEP, R-CVP, CVP or&#xD;
             simi-lar), Bortezomib (VCD, MPV, VRD or similar) or Lenalidomide (VRD, len-dex or&#xD;
             similar) regardless of type of haematological malignancy&#xD;
&#xD;
          -  Not started chemotherapy treatment before enrollment (pretreatment with steroids is&#xD;
             allowed)&#xD;
&#xD;
          -  Associated to Department of Haematology, Aalborg University Hospital during the&#xD;
             project period&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Able to read and speak Danish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known vitamin B12 deficiency and treated with either oral or intramuscular vitamin B12&#xD;
             within the last year&#xD;
&#xD;
          -  Known neural damage or disease in the neural system (e.g. MS, Guillain-Barre etc.)&#xD;
&#xD;
          -  Known severe skin disease&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Inability to understand or comply with instructions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne T Severinsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne T Severinsen, MD, PhD</last_name>
    <phone>+45 97663861</phone>
    <email>m.severinsen@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva F Maksten, MD</last_name>
    <email>efm@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Haematology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne T Severinsen, MD, PhD</last_name>
      <email>m.severinsen@rn.dk</email>
    </contact>
    <contact_backup>
      <last_name>Eva F Maksten, MD</last_name>
      <email>efm@rn.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Marianne Tang Severinsen</investigator_full_name>
    <investigator_title>Consultant, Head of Research, Ass. Professor</investigator_title>
  </responsible_party>
  <keyword>vincristine</keyword>
  <keyword>bortezomib</keyword>
  <keyword>lenalidomide</keyword>
  <keyword>Assessment of nerve fiber excitability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

